Successful Oral Administration of PYY 3-36
SSNe Nano-Encapsulation and Serum Disposition
of Peptide YY 3-36 Per Oral Administration
Daniel R. DeBrouse, Ph.D, CEO, CSO Tamarisk Technologies, LLC Department of
Molecular Biology, Oklahoma Division of Pharmacology, February 2012
Obesity has become a worldwide epidemic and its prevalence is increasing at an alarming rate. In 2010, according to the CDC US Obesity trends Behavioral Risk Factor Surveillance System (BRFSS), approximately one-third of all US adults (33.8%) and 12.5 million children and adolescents aged 2-19 years were reported to be obese.
The global negative impacts of obesity include health, social and economic consequences. For example, both mortality and morbidity rates are higher among overweight and obese individuals than that of lean people. Further, a BMI of greater than 30 has been conclusively linked to a greater incidence of coronary heart disease, hypertension, hyperlipidemia, NIDDM, diabetes and certain cancers. The pathological features associated with obesity are major causes of illness and death worldwide. If obesity rates continue to climb it will soon supplement smoking as the primary cause of preventable death.
The social burdens created by obesity prevalence are massive and together with health burdens often over-shadow the resulting economic cost to society and to the obese individual. In 1995 alone the total US economic cost attributed to obesity was a staggering 99 billion dollars.
Despite the recognition that moderate weight loss confers significant health benefits, to date there have been few effective therapies for obesity. This is certainly not due to a lack of knowledge regarding the key regulatory pathway and the corresponding regulatory peptides, cell lines and receptors involved in hunger signaling in the gastrointestinal tract and brain. In fact, throughout the course of the last 30 plus years, numerous studies have continually implicated the anorectic effects of Peptide YY (PYY). In every case study, subcutaneous administration of PYY3-36, in both rodents and human subjects, has led to a rapid reduction in body weight and improved glycemic control in glucose-intolerant subjects, indicative of a key therapeutic role of PYY 3-36 in appetite and weight control in obese individuals.
In the proceeding study, we present the nano-encapsulation of PYY 3-36 in Tamarisk’s SSNe transport vehicle, it's oral administration, serum disposition within rodents, and demonstrate results in reduced calorie intake, food consumption, and weight loss consistent with those widely reported upon repeated intravenous infusion of PYY 3-36 in rodents and humans (continued)...
Read the Full Report- Click Here
Related Articles
3rd Party Evaluation Study of Resveratrol Encapsulated within Tamarisk's SSNe Drug Delivery - Click Here
(SSNe) Serum-Specific Drug Transport- Click Here
Oral Insulin Report- Click Here
Oral Peptide YY 3-36 - Click Here
For more information about Tamarisk's Serum Specifc, Tissue Specific, and Extended Release technologies, contact the DelivRX team today at licensing@tamarisktech.com or call our office at 405-279-1250.
The documents on this web site could include technical inaccuracies or typographical errors. Please report any errors to Tamarisk Technologies Customer Service.
